While Beam Therapeutics Inc has overperformed by 5.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BEAM fell by -33.05%, with highs and lows ranging from $40.65 to $20.84, whereas the simple moving average jumped by 2.69% in the last 200 days.
On January 29, 2025, Cantor Fitzgerald Upgraded Beam Therapeutics Inc (NASDAQ: BEAM) to Overweight. A report published by Leerink Partners on November 06, 2024, Upgraded its rating to ‘Outperform’ for BEAM. H.C. Wainwright Initiated an Buy rating on July 23, 2024, and assigned a price target of $80. JP Morgan January 29, 2024d its ‘Neutral’ rating to ‘Overweight’ for BEAM, as published in its report on January 29, 2024. BofA Securities’s report from December 15, 2023 suggests a price prediction of $35 for BEAM shares, giving the stock a ‘Neutral’ rating. Jefferies also rated the stock as ‘Hold’.
Analysis of Beam Therapeutics Inc (BEAM)
Further, the quarter-over-quarter decrease in sales is -90.49%, showing a negative trend in the upcoming months.
One of the most important indicators of Beam Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -43.94% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and BEAM is recording 1.26M average volume. On a monthly basis, the volatility of the stock is set at 8.26%, whereas on a weekly basis, it is put at 9.41%, with a loss of -11.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $48.50, showing growth from the present price of $26.44, which can serve as yet another indication of whether BEAM is worth investing in or should be passed over.
How Do You Analyze Beam Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.95%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 83.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BEAM shares are owned by institutional investors to the tune of 83.37% at present.
